Time Course Of Tolerance Research Articles

Time Course and Magnitude of Tolerance to the Ergogenic Effect of Caffeine on the Second Ventilatory Threshold.

Pre-exercise caffeine ingestion has been shown to increase the workload at ventilatory threshold, suggesting an ergogenic effect of this stimulant on submaximal aerobic exercise. However, the time course of tolerance to the effect of caffeine on ventilatory threshold is unknown. This study aimed to determine the evolution of tolerance to the ergogenic effect of caffeine on the ventilatory threshold. Methods: Eleven participants (age 32.3 ± 4.9 yrs, height 171 ± 8 cm, body mass 66.6 ± 13.6 kg, VO2max = 48.0 ± 3.8 mL/kg/min) took part in a longitudinal, double-blind, placebo-controlled, randomized, crossover experimental design. Each participant took part in two identical treatments: in one treatment, participants ingested a capsule containing 3 mg of caffeine per kg of body mass per day (mg/kg/day) for twenty consecutive days; in the other treatment, participants ingested a capsule filled with a placebo for the same duration and frequency. During these treatments, participants performed a maximal ramp test on a cycle ergometer three times per week and the second ventilatory threshold (VT2) was assessed by using the ventilatory equivalents for oxygen and carbon dioxide. Results: A two-way ANOVA with repeated measures (substance × time) revealed statistically significant main effects of caffeine (p < 0.01) and time (p = 0.04) on the wattage obtained at VT2, although there was no interaction (p = 0.09). In comparison to the placebo, caffeine increased the workload at VT2 on days 1, 4, 6 and 15 of ingestion (p < 0.05). The size of the ergogenic effect of caffeine over the placebo on the workload at VT2 was progressively reduced with the duration of the treatment. In addition, there were main effects of caffeine (p = 0.03) and time (p = 0.16) on VO2 obtained at VT2, with no interaction (p = 0.49). Specifically, caffeine increased oxygen uptake at VT2 on days 1 and 4 (p < 0.05), with no other caffeine–placebo differences afterwards. For heart rate obtained at VT2, there was a main effect of substance (p < 0.01), while the overall effect of time (p = 0.13) and the interaction (p = 0.22) did not reach statistical significance. Heart rate at VT2 was higher with caffeine than with the placebo on days 1 and 4 (p < 0.05). The size of the effect of caffeine on VO2 and heart at VT2 tended to decline over time. Conclusion: Pre-exercise intake of 3 mg/kg/day of caffeine for twenty days enhanced the wattage obtained at VT2 during cycling ramp tests for ~15 days of ingestion, while there was a progressive attenuation of the size of the ergogenic effect of caffeine on this performance variable. Therefore, habituation to caffeine through daily ingestion may reduce the ergogenic effect of this stimulant on aerobic exercise of submaximal intensity.

Time course of tolerance to the performance benefits of caffeine.

The ergogenic effect of acute caffeine ingestion has been widely investigated; however, scientific information regarding tolerance to the performance benefits of caffeine, when ingested on a day-to-day basis, is scarce. The aim of this investigation was to determine the time course of tolerance to the ergogenic effects of a moderate dose of caffeine. Eleven healthy active participants took part in a cross-over, double-blind, placebo-controlled experiment. In one treatment, they ingested 3 mg/kg/day of caffeine for 20 consecutive days while in another they ingested a placebo for 20 days. Each substance was administered daily in an opaque unidentifiable capsule, and the experimental trials started 45 min after capsule ingestion. Two days before, and three times per week during each 20-day treatment, aerobic peak power was measured with an incremental test to volitional fatigue (25 W/min) and aerobic peak power was measured with an adapted version of the Wingate test (15 s). In comparison to the placebo, the ingestion of caffeine increased peak cycling power in the incremental exercise test by ~4.0 ±1.3% for the first 15 days (P<0.05) but then this ergogenic effect lessened. Caffeine also increased peak cycling power during the Wingate test on days 1, 4, 15, and 18 of ingestion by ~4.9 ±0.9% (P<0.05). In both tests, the magnitude of the ergogenic effect of caffeine vs. placebo was higher on the first day of ingestion and then progressively decreased. These results show a continued ergogenic effect with the daily ingestion of caffeine for 15–18 days; however, the changes in the magnitude of this effect suggest progressive tolerance.

Time course of tolerance to ischemia-reperfusion injury and induction of heat shock protein 72 by heat stress in the rat heart.

We compared the time course of tolerance to myocardial ischemia-reperfusion injury with the time course of heat shock protein 72 (hsp72; inducible form) induction after heat stress in a rat model. The size of the infarct resulting from ischemia-reperfusion was increased 12 h after whole-body hyperthermia (42 degrees C for 15 min), but was significantly decreased 48 and 72 h after hyperthermia, compared with the sham control. The infarct size was decreased as late as 96 h after hyperthermia, although the infarct-limiting effect was smaller at that time. The myocardial content of hsp72 was markedly increased for 3-72 h after hyperthermic treatment, and was decreased after 72 h in association with an increase in the infarct size. The hsp72 content remained elevated during the period of tolerance to ischemia-reperfusion injury, but the infarct size decreased after the hsp72 content peaked. Pretreatment with a protein kinase C (PKC) inhibitor, chelerythrine chloride, immediately before hyperthermia, significantly suppressed the delayed cardioprotective effect of hyperthermia and reduced hsp72 induction. These results suggest that newly synthesized hsp72 through PKC activation after heat stress may have to be post-translationally modified and compartmentalized prior to assuming to the development of the delayed tolerance to ischemia-reperfusion injury in rats.

Time course and magnitude of tolerance to the analgesic effects of systemic morphine in amphibians

The systemic administration of morphine (100 nmol/g, s.c.) produced a significant and long-lasting analgesia (up to 8 h) in the Northern grass frog, Rana pipiens. Daily bolus injections of the same dose of morphine or saline for one week resulted in a significant analgesia for 3 days in the morphine group, which fell to levels indistinguishable from the saline-treated controls on days 4 through 7. In separate experiments, animals were treated identically with morphine or saline but were not tested daily for pain thresholds. In these animals, administration of a range of morphine doses on day 8 yielded dose-response curves significantly-shifted rightward by a factor of 3.3 in the morphine-treated group compared to the saline-injected controls. These studies are the first to show the time course of tolerance development and the magnitude of morphine tolerance in a non-mammalian vertebrate species.

Time course and magnitude of tolerance to the analgesic effects of systemic morphine in amphibians.

The systemic administration of morphine (100 nmol/g, s.c.) produced a significant and long-lasting analgesia (up to 8 h) in the Northern grass frog, Rana pipiens. Daily bolus injections of the same dose of morphine or saline for one week resulted in a significant analgesia for 3 days in the morphine group, which fell to levels indistinguishable from the saline-treated controls on days 4 through 7. In separate experiments, animals were treated identically with morphine or saline but were not tested daily for pain thresholds. In these animals, administration of a range of morphine doses on day 8 yielded dose-response curves significantly-shifted rightward by a factor of 3.3 in the morphine-treated group compared to the saline-injected controls. These studies are the first to show the time course of tolerance development and the magnitude of morphine tolerance in a non-mammalian vertebrate species.

Time course of tolerance to apomorphine in parkinsonism.

We sought to determine if tolerance developed to the antiparkinsonian effects of apomorphine and, if so, what temporal factors influenced its development. Seven patients with parkinsonism and motor fluctuations received short (6-hour) and long (22- to 31-hour) apomorphine infusions. Tolerance was evaluated by comparison of the responses to test doses of apomorphine that were administered before and after each infusion. The responses to the test doses that followed either infusion were reduced by 35% after the short infusion and by 68% after the long infusion, although plasma apomorphine levels were similar to or higher than levels achieved with preinfusion test doses. The duration of improvement in parkinsonism after discontinuation of the long infusion was briefer than that after the short infusion. We conclude that tolerance to apomorphine occurs in parkinsonism, and the loss of response is greater after longer periods of drug administration.

Tolerance to the hyperactivating effects of methylamphetamine.

The development of tolerance to the hyperactivating effects of methylamphetamine was studied in the laboratory rat. The results of Experiment I indicated that tolerance did develop. In Experiment II these indications were confirmed and the time course of tolerance was plotted. It appeared that the development of tolerance could be divided into two phases: an initial period of about one week during which activity increased, possibly due to accumulation of the drug or a metabolite, and a later period lasting about six weeks during which activity gradually fell to the first day of drug administration.

Effects of delta-9-tetrahydrocannabinol on temporal and auditory discrimination performances of monkeys.

In two experiments, macaques were trained to respond differentially to either the duration of a visual stimulus or to the frequency of an auditory clicker. In the duration discrimination experiment, delta-9-tetrahydrocannabinol (delta-9-THC) was administered acutely in doses from 1 to 16 mg/kg, producing dose-related decrements in accuracy of the discrimination performance, and a reduction in the rate at which the animals initiated discrimination trials. In both the duration and auditory discrimination experiments, chronic daily administrations of 2 to 16 mg/kg of delta-9-THC produced an initial decrement in accuracy and rate of trial initiation. Both measures showed some development of tolerance, tending to return to baseline levels, however, the time course of tolerance was different for the measures, with the rate of trial initiation recovering more quickly than accuracy. No differences in response to the drug were attributable to the different modalities used in these two experiments.